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ABSTRACT
Current reports for oral hypoglycemic agents (OHAs) are described. As to the association of  dipeptidyl peptidase-4 inhibitors (DPP-
4i) and bullous pemphigoid (BP), odds ratio (OR) was vildagliptin 5.08, linagliptin 2.87, sitagliptin 1.29 (not significant). Regarding 
the comparative study between SGLT2i and DPP-4i, SGLT2i group showed lower hazard ratio (HR) as MACE 0.76, myocardial 
infarction 0.82, cardiovascular death 0.60, heart failure 0.43, all-cause mortality 0.60. Semaglutide showed reduced OR for cardiovas-
cular death than exenatide 0.47, dulaglutide 0.46, albiglutide 0.45, lixisenatide 0.43. SGLT2i showed reduction risk of  HR for MACE 
0.90, hospitalization for heart failure (HHF)/cardiovascular death 0.78, renal outcomes 0.62.
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INTRODUCTION
Standard guideline for diabetes mellitus in 2021 was presented by American Diabetes Association (ADA).1 Recent topics for 
oral hypoglycemic agents (OHAs) will be introduced here with 
clinical evidence of  larger studies. The episodes of  hypoglycemia 
are risk factors for cardiovascular prognosis. A cohort study exam-
ining the prognosis of  74,610 patients for type 2 diabetes mellitus 
(T2DM) was reported.2 After follow-up of  7.1-years in median, the 
absolute 5-year risk of  death was 6.6% for cardiovascular death, 
1.1% for cancer deaths, and 13.1% for other deaths in hospitalized 
group (n=388) for severe hypoglycemia, respectively. In contrast, 
the group who was not hospitalized for severe hypoglycemia had 
cardiovascular deaths 4.7%, cancer deaths 1.4%, and other deaths 
11.1%, which were lower than those who experienced hypoglyce-
mia, respectively. 
 Dipeptidyl peptidase-4 inhibitors (DPP-4i) has been 
recently prevalent. A systematic review was reported on the ef-
ficacy of  DPP-4i for cardiovascular disease, and 18 randomized 
controlled trials (RCTs) and meta-analyses were analyzed.3 As a re-
sult, no additional benefit to cardiovascular risk could be expected 
when DPP-4i was added to standard treatment. Some studies are 
found concerning DPP-4i and bullous pemphigoid (BP). For 138 
RCTs, including 61514 DPP-4 inhibitor users and 59661 subjects 
were analyzed.4 Among them, only 6 studies reported BP. As a 
result of  meta-analysis, an odds ratio (OR) of  4.44 was found to 
be significantly associated with this risk. Meta-analysis study was 
conducted for evaluating the risk of  BP and skin-related adverse 
events (AEs). Totally, 46 randomized placebo-controlled trials 
(n=59332) were included.5 Among them, 3 studies revealed BP 
(n=38011), which included AEs. Comparison with control group, 
DPP4i group showed significantly higher-risk (OR 7.38). More-
over, DPP-4i therapy revealed increased overall risk of  AEs (OR 
1.22 p=0.03). To evaluate the relationship for BP, 5 studies for dif-
ferent kinds of  DPP-4i were analyzed.6 From adjusted meta-anal-
ysis, significant association between them were observed as OR 
2.13. The OR was 5.08 in vildagliptin, 2.87 in linagliptin, while OR 
1.29 (not significant p=0.31) in sitagliptin. By subgroup analysis, 
the OR in male was 2.35 and 1.88 in female. Consequently, the 
adjusted analysis can support a significant association of  DPP-4i 
use and BP.
 Comparative study was performed between sodium/glu-
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cose cotransporter-2 inhibitors (SGLT2i) and DPP-4i. A retrospec-
tive cohort study for cardiovascular risk was reported using large 
databases in Canada and UK.7 Subjects included matched 209,867 
cases each for users of  SGLT2i and DPP-4i. The primary outcome 
was major adverse cardiovascular events (MACE) and secondary 
outcomes were individual MACE, heart failure, and mortality of  
all causes. SGLT2i group for 0.9-years showed lower hazard ra-
tio (HR) as MACE 0.76, myocardial infarction 0.82, cardiovascu-
lar death 0.60, heart failure 0.43, all-cause mortality 0.60, ischemic 
stroke 0.85. Similar beneficial effect for MACE were found with 
canagliflozin (0.79), dapagliflozin (0.73), and empagliflozin (0.77). 
Thus, the short-term use of  SGLT2i can reduce the cardiovascular 
risks, compared with DPP-4i. 
 Semaglutide has been a topic for oral agent of  GLP-1a. 
Systematic review for the effect of  semaglutide was conducted in 
11 RCTs with 9890 cases.8 The results showed that hemoglobin 
A1C (HbA1c) decreased 0.89% and body weight decreased 2.99 
kg, respectively. Semaglutide showed superiority of  decreased 
HbA1c/weight as -0.35%/-1.48 kg, compared with sitagliptin, em-
pagliflozin and liraglutide. Furthermore, semaglutide decreased all-
cause mortality (OR 0.58) and cardiovascular mortality (OR 0.55), 
and showed the neutral efficacy for stroke, myocardial infarction, 
diabetic retinopathy and hypoglycemia. Seven cardiovascular out-
come trials (CVOTs) were conducted including 56004 patients us-
ing network meta-analysis (NMA).9 Semaglutide showed reduced 
OR of  cardiovascular death statistically than exenatide 0.47, du-
laglutide 0.46, albiglutide 0.45, lixisenatide 0.43. In contrast, sig-
nificant differences were not detected for reducing death from any 
case, stroke and MI events. Consequently, GLP-1RAs revealed sig-
nificant benefits for cardiovascular safety.
 Regarding SGLT2i, several recent reports are found. The 
cardiovascular efficacy of  ertugliflozin was evaluated for the study 
of  VERTIS CV. T2DM cases (n=8246) received ertugliflozin or 
placebo, and a major adverse cardiovascular event (MACE) was 
analyzed for 3.5-years.10 OR were 0.97 for MACE, 0.88 for death 
or hospitalization for heart failure (HHF). Hazard ratio (HR) for 
death from cardiovascular causes was 0.92, and death from renal 
causes was 0.81. Thus, ertugliflozin was proved to be non-inferior 
to placebo for MACE. In order to assess the renal and cardiovas-
cular outcomes of  T2DM for SGLT2i agents, analysis of  system-
atic literature search was conducted.11 The data were from 46969 
T2DM cases including 31116 cases of  cardiovascular disease. The 
results showed reduction risk of  MACE (HR 0.90), HHF/car-
diovascular death (HR 0.78), renal outcomes (HR 0.62). Conse-
quently, SGLT2i showed reduced risk of  MACE, HHF and renal 
outcomes, associated with beneficial effects of  HHF risk that is 
consistent findings across the trials.
 Chronic kidney disease (CKD) patients have elevated risk 
of  adverse cardiovascular and renal outcomes. Clinical efficacy of  
dapagliflozin was studied for CKD patients as dapagliflozin and 
prevention of  adverse outcomes in chronic kidney disease (DAPA-
CKD) trial.12 Randomly assigned 4304 cases with estimated glo-
merular filtration rate (eGFR) 25-75 mL/min/1.73 m2 and urinary 
Alb/Cre ratio (200-5000) were investigated and provided dapa-
gliflozin or placebo. The primary outcome included a sustained 
eGFR decline, end-stage kidney disease (ESKD) or death from 
kidney or cardiovascular causes. HRs were primary outcome event 
0.61, sustained eGFR decline 0.56 and death for various cause 0.69. 
The results were similar for patients with/without T2DM. Conse-
quently, safer profile of  dapagliflozin was confirmed. The study 
was apparently effective and then discontinued early, for 2.4-years 
in median. 
 SGLT2i may reduce the risk of  HHF. For 3730 patients 
with heart failure with class II, III, IV and <40% of  ejection frac-
tion, double-blind trial was conducted by providing empagliflozin 
10 mg a day or control as EMPEROR-Reduced Trial.13 Primary 
outcome was HHF or cardiovascular death. During 16-months, 
primary outcome event was observed in 19.4% in empagliflozin 
group, and 24.7% in control group (HR 0.75). The total number of  
HHF was lower in empagliflozin group (HR 0.70). Annual decline 
of  eGFR was slower in empagliflozin group (-0.55 vs. -2.28 ml/
min/1.73 m2/year, p<0.001). Consequently, patients in the empa-
gliflozin group showed lower risk of  cardiovascular death or HHF, 
irrespective of  the presence or absence of  diabetes.
 Concerning the relationship between SGLT2i and lower 
extremity amputation outcomes, 12 RCTs and 18 observational 
studies were investigated.14 Meta-analysis of  7 RCTs has brought 
absence of  significant association as RR 1.28. From sub-group 
analysis, canagliflozin showed significantly increased risk in meta-
analysis (RR 1.59) (2 RCTs), while dapagliflozin or empagliflozin 
did not show a significantly increased risk (2 RCTs each). Gener-
ally, no consistent evidence of  increased risk was not found. An-
other study of  adverse limb event was performed from 6 reports.15 
They include canagliflozin (CANVAS, CREDENCE), empa-
gliflozin (EMPA-REG OUTCOME), ertugliflozin (VERTIS CV) 
and dapagliflozin (DECLARE-TIMI 58, DAPA-HF trials). Out of  
51713 cases, 858 had amputation operations. The amputation ratio 
was 2.0/1.3% in SGLT-2i/control group, as pooled risk ratio of  
1.24. From this analysis, SGLT-2i is not statistically associated with 
increased risks of  amputation operations.
CONCLUSION
In summary, recent meaningful reports were introduced. The in-
formation will be hopefully useful for future research and practice 
for diabetes mellitus. 
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